A robust and reliable culture system of adult stem cells is essential for applying the cutting-edge technologies of drug screening, gene editing, and genomics to stem cell research necessary for breakthroughs in this field. In addition, personalized regenerative medicine based on autologous transplantation requires our ability to clone and expand the numbers of these stem cells in vitro. In comparison to the 3D "organoid" culture system that shows limited ability to propagate stem cells as the majority of cells are differentiated or transit amplifying cells, ground-state stem cell culture system is a novel technology that permits long-lived adult stem cells to maintain immaturity, self-renewal capacity, multi-potency and genomic stability despite long-term culturing in a 2D system. The robustness, reliability and easy-to-use features of this new technology bypass the deficiencies of 3D organoid culture systems and provided unlimited stem cell sources for research, therapeutic use, and drug discovery.
The history of 3T3-J2 feeder system in adult stem cell culturing
The 3T3-J2 feeder system was generated by Howard Green's lab in 1975 and since has been employed to culture various types of adult stem cells derived from stratified epithelium such as skin, cornea, thymus and lung 1, 2 . Importantly, the J2 strain of 3T3 cells cleared regulatory hurdles for clinical more than thirty years ago without reports of adverse effects [3] [4] [5] . Despite the development of several feeder-free cell culture methods [6] [7] [8] , methods based on the Rheinwald and Green culture protocol remain as the gold standard for clinical applications 4 because of its high clonogenicity and regenerative capacity. However, regulatory considerations and the extensive time and effort required for preparation of murinederived feeder cells in this system limit the use of these stem cells for downstream applications including regenerative medicine. Thus, moving towards feeder-free culture system for adult stem cells would represent an essential and important improvement.
Despite the remarkable track record of the Green method for cloning stem cells of stratified epithelia, it proved ineffective for cloning stem cells of columnar epithelia such as the liver, gastrointestinal tract, and kidney. Therefore, we developed a new technology using a combination of 3T3-J2 feeder cells and a specialized medium to clone ground-state stem cells from human fetal and adult columnar epithelium [9] [10] [11] . Importantly, this system enables the maintenance of stem cells with extremely high clonogenicity in culture so sufficient numbers required for downstream applications can be reached in a short time. In addition, the adult stem cells cultured in these feeder systems maintain the ability of regiospecific differentiation 1, 9, 12, 13 .
Comparison between organoids and ground-state stem cell cloning technology
Since the 1980s, the researchers began to use 3D culture systems in which mammalian cells are grown in collagen and laminin-rich matrices as organoids [14] [15] [16] [17] [18] . Organoid technology has allowed some fundamental advances in stem cell research, however, it doesn't support culturing the intestinal stem cells or any other adult stem cells in their highly clonogenic and immature state. Importantly, the transit amplifying cells that have lost stem cell capacity can also generate organoids because they still have limited proliferative potential, thus organoids are not assays for stem cells 19 .
The ground-state stem cell cloning technology solved the problem of cloning and culturing of highly-clonogenic stem cells derived from both fetal and adult human gastrointestinal tract epithelium. This system includes 3T3-J2 feeder cells and a specialized media using a cocktail of factors impacting Wnt, Notch, and TGF-beta signaling pathways among others 9, 11 . Significantly, using this system, normal stem cells of stomach, intestine as well as stem cells of precancerous lesions such as Barrett's esophagus can be cloned from 1mm endoscopic biopsies 10, 11 . Furthermore, we anticipate that this technology can also support cloning and culturing of stem cells of other columnar epithelium such as pancreas and liver. Therefore, stem cells of columnar epithelia can be routinely captured and cultured in the same ground state that Howard Green had shown for the stem cells of epidermis.
In comparison with widely used organoid systems, we found the following properties of these ground-state stem cells make this technology particularly advantageous: 1. We can generate approximately 100 stem cell clones from a typical 1mm endoscopic biopsy, which preserves the potential clonal diversity of intestinal crypts; 2. We can expand each of these clones as pedigrees and reach 1 billion progeny cells in approximately sixty days. This unique feature allows us to obtain sufficient cell number rapidly for time-sensitive applications such as autologous transplantation. 3. These stem cells maintain genomic integrity despite long-term culturing which reduces safety concerns for using them for regenerative medicine. 4. The cultured ground-state stem cells uniformly express stem cell markers and have high clonogenicity rate of 60-90%; 5. The ground state stem cell clones retain permanent epigenetic memory of regiospecificity. 6. The ground state stem cells maintain long-term multipotent differentiation ability so the stem cells of a single cell derived pedigree can be differentiated to yield 3-D intestinal epithelia with regionally appropriate cell types despite extensive cultivation in vitro. 7. We can clone stem cells from all donors despite age, sex, and disease status and maintain comparable clonogenicity of cultured stem cells across patients.
The future applications of ground-state stem cells
Our ability of producing unlimited number of adult stem cells in culture provides the opportunities of rapidly advancing their utility in disease modeling, drug discovery, biobanking, and personalized regenerative medicine, Since stem cells can be derived from both normal and diseased tissue, expanded in culture and induced to differentiate into artificial 3D tissue that recapitulate their in vivo counterparts, they are ideal model system for investigating the cellular and molecular mechanisms underlying these diseases. If the long-term regenerative growth of diseased stem cells is distinct from those that support the nearby normal epithelium, these differences should render diseased stem cells selectively targetable 20 .
The rapid expansion of ground-state stem cells provides sufficient number of cells enabling moderate and even high-throughput testing of small molecule, biologics, or even immunologic approaches to the selective eradication of the diseased stem cells in a manner that would spare those of normal epithelia. It is conceivable that if such studies are validated both in vitro and in vivo, they could yield small molecules and biologics that could be used to improve patient care and outcome.
For personalized regenerative medicine, Howard Green and colleagues demonstrated the feasibility of cultured wild-type or genetically-modified adult stem cells being transplanted to patients for the purpose of regenerative medicine. This is a life-saving procedure for patients with large area of burns or with severe genetic disease [21] [22] [23] . We anticipate that this newfound ability to derive ground-state stem cells from columnar epithelium provides excellent sources for autologous transplantation to treat a wide range of disorders which current treatments are not able to help. For example, the intestinal epithelial functions in patients with severe forms of short bowel syndrome (SBS) 24 , or those with congenital disorders 25 or inflammatory bowel disease (IBD) 26,27 may be restored following autologous transplantation of cultured wild-type or genetically-edited ground-state intestinal stem cells. Furthermore, more and more stem cell researchers may realize the potential of biobanking various types of adult stem cells from individuals of diverse HLA haplotypes and make attempts to use them for stem-cell-based personalized regenerative medicine.
Taken together, with the recognition and utilization of ground-state stem cell cloning technology in research and medicine, we hope that in the foreseeable future
